Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis
Abstract
Abstract. Low concentrations of serum vitamin K accompany high concentrations of undercarboxylated osteocalcin (ucOC) and osteoporotic fractures. Although vitamin K2 (MK-4) is approved as a therapeutic agent for the treatment of osteoporosis in some countries, the dose-response is unknown. The objective of this study was to assess the improvement in carboxylation of osteocalcin (OC) in response to escalating doses of MK-4 supplementation. A nine-week, open-labeled, prospective cohort study was conducted in 29 postmenopausal women who suffered hip or vertebral compression fractures. Participants took low-dose MK-4 (0.5 mg) for 3 weeks (until the second visit), then medium-dose MK-4 (5 mg) for 3 weeks (until the third visit), then high-dose MK-4 (45 mg) for 3 weeks. The mean ± SD age of the participants was 69 ± 9 years. MK-4 dose (p < 0.0001), but neither age nor other relevant medications (e.g. bisphosphonates) correlated with improvement in %ucOC. As compared to baseline concentrations (geometric mean ± SD) of 16.8 ± 2.4, 0.5 mg supplementation halved %ucOC to 8.7 ± 2.2 (p < 0.0001) and the 5-mg dose halved %ucOC again (to 3.9 ± 2.2; p = 0.0002 compared to 0.5-mg dose). However, compared to 5 mg/day, there was no additional benefit of 45 mg/day (%ucOC 4.6; p = NS vs. 5-mg dose). MK-4 supplementation resulted in borderline increases in γ-carboxylated osteocalcin (glaOC; p = 0.07). There were no major side effects of MK-4 supplementation. In postmenopausal women with osteoporotic fractures, supplementation with either 5 or 45 mg/day of MK-4 reduces ucOC to concentrations typical of healthy, pre-menopausal women.
References
1 (1995) How many women have osteoporosis now? J Bone Miner Res. 10, 175–7.
2 (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 128, 793–800.
3 (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc. 51, 364–70.
4 (2012) Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. Pharmacoeconomics. 30, 147–70.
5 (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280, 605–13.
6 (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 288, 321–33.
7 (2012) Evidence-based assessment of the impact of the WHI on women’s health. J of Int Menopause Soc. 15, 281–7.
8 (2000) Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 71, 1201–8.
9 (2004) Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 89, 4904–9.
10 (1997) Serum vitamin K level and bone mineral density in post-menopausal women. Int J Gynaecol Obstet. 56, 25–30.
11 (1993) Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 8, 1241–5.
12 (1999) Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 69, 74–9.
13 (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 69, 990–1047.
14 (1993) Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis. Am J Med. 95, 11S–16S.
15 (1985) Vitamin K-dependent carboxylase. Annu Rev Biochem. 54, 459–77.
16 (1998) Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab. 83, 3258–66.
17 (1994) Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res. 9, 1591–5.
18 (1996) Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int. 59, 352–6.
19 (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 91, 1769–74.
20 (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone. 18, 487–8.
21 (1997) Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int. 51, 1218–21.
22 (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 82, 719–24.
23 (2002) A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation. Am J Clin Nutr. 76, 1055–60.
24 (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 15, 515–21.
25 (2002) Time-dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr J. 49, 363–70.
26 (1998) Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. Calcif Tissue Int. 63, 375–9.
27 (1993) Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. Calcif Tissue Int. 53, 81–5.
28 (2003) Dietary phylloquinone depletion and repletion in older women. J Nutr. 133, 2565–9.
29 (2000) Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr. 72, 1523–8.
30 (2003) Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab. 21, 161–5.
31 (2009) Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women. J Nutr Sci Vitaminol (Tokyo). 55, 15–21.
32 (1995) Carboxylation of osteocalcin in post-menopausal osteoporotic women following vitamin K and D supplementation. Bone. 17, 15–20.
33 (2013) Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 24, 2499–507.
34 (1997) Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr. 65, 779–84.
35 (2010) Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporosis International. 21, 1731–40.
36 (2008) Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab. 93, 1217–23.
37 (2006) Vitamin K and the prevention of fractures: Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 166, 1256–61.
38 (2003) Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int. 73, 21–6.
39 (2012) Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr. 3, 149–57.
40 (2006) Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. Am J Clin Nutr. 83, 380–6.
41 (2012) Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 59, 186–95.
42 (2012) Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects. Br J Nutr. 108, 1652–57.
43 (2011) The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. Kurume Med J. 57, 117–24.
44 (2008) Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Medicine. 5, 1–2.
45 (2009) Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res. 24, 983–91.
46 (2017) Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab. 35, 385–395.
47 (2016) Bioavailability and Chemical/Functional Aspects of Synthetic MK-7 vs Fermentation-Derived MK-7 in Randomised Controlled Trials. Int J Vitam Nutr Res. 1–15.
48 (1940) Oral and Parenteral Toxicity of Vitamin K1, Phthiocol and 2 Methyl 1, 4, Naphthoquinone. Exp Biol Med. 43, 125–28.
49 . (2001) Dietary Reference intakes for vitamin A, vitamin K, arsenic boron, chromium, copper, iodine, iron, manganese, molybdenom, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press.
50 (2005) Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer’s disease. Bone. 36, 61–8.
51 (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Mineral Metab. 27, 66–75.
52 (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the national registry of atrial fibrillation 2. Arch Intern Med. 166, 241–6.
53 . Calcium and Vitamin D: What You Need to Know. [cited 2013 Sept 15]; Available from: http://www.nof.org/articles/10
54 (1991) A one step sandwich enzyme immunoassay for gamma-carboxylated osteocalcin using monoclonal antibodies. J Immunol Methods. 139, 17–23.
55 (1990) Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K-dependent carboxylase. Biochim Biophys Acta. 1034, 170–75.
56 (1996) Vitamin K2 promotes 1alpha, 25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int. 59, 466–73.
57 (2000) Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 30, 298–307.
58 (2006) Dietary phylloquinone depletion and repletion in postmenopausal women: effects on bone and mineral metabolism. Osteoporos Int. 17, 929–35.
59 (2013) Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 83, 835–44.
60 (2012) Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 11(93), 1–4.
61 (2007) Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 18, 963–72.
62 (1996) Increased bone formation in osteocalcin-deficient mice. Nature. 382, 448–52.
63 (1998) Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone. 23, 187–96.
64 (2012) Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab. 30, 60–8.